aminosalicylic acid has been researched along with Extensively Drug-Resistant Tuberculosis in 13 studies
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.
4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.
Extensively Drug-Resistant Tuberculosis: Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index." | 6.79 | Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. ( de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014) |
| "Para-aminosalicylic acid (PAS) is again needed for the treatment of multidrug and extensively drug-resistant tuberculosis (M/XDR-TB)." | 3.80 | French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS(®) in MDR-TB patients. ( Kibleur, Y; Veziris, N, 2014) |
| " A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index." | 2.79 | Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. ( de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014) |
| " In this Review, we assess published work regarding recommendations for PAS dosing in relation to efficacy and tolerance." | 2.52 | Para-aminosalicylic acid: the return of an old friend. ( Diacon, AH; Donald, PR, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Krátký, M | 1 |
| Vinšová, J | 1 |
| Buchta, V | 1 |
| Horvati, K | 1 |
| Bösze, S | 1 |
| Stolaříková, J | 1 |
| Li, Z | 1 |
| Liu, F | 1 |
| Chen, H | 1 |
| Han, Y | 1 |
| You, Y | 1 |
| Xie, Y | 1 |
| Zhao, Y | 1 |
| Tan, J | 1 |
| Guo, X | 1 |
| Cheng, Y | 1 |
| Wang, Y | 1 |
| Li, J | 1 |
| Cheng, M | 1 |
| Xia, S | 1 |
| Niu, X | 1 |
| Wei, L | 1 |
| Wang, W | 1 |
| Saroha, D | 1 |
| Garg, D | 1 |
| Singh, AK | 1 |
| Dhamija, RK | 1 |
| Caminero, JA | 1 |
| Piubello, A | 1 |
| Scardigli, A | 1 |
| Migliori, GB | 1 |
| Kuo, CY | 1 |
| Wang, WH | 1 |
| Huang, CH | 1 |
| Chen, YH | 1 |
| Lu, PL | 1 |
| de Kock, L | 1 |
| Sy, SK | 1 |
| Rosenkranz, B | 1 |
| Diacon, AH | 2 |
| Prescott, K | 1 |
| Hernandez, KR | 1 |
| Yu, M | 1 |
| Derendorf, H | 1 |
| Donald, PR | 2 |
| Li, N | 1 |
| Liao, X | 1 |
| Chen, L | 1 |
| Wang, J | 1 |
| Liu, M | 1 |
| Zhang, H | 1 |
| Kibleur, Y | 1 |
| Veziris, N | 1 |
| Shean, K | 1 |
| Siwendu, S | 1 |
| van der Walt, M | 1 |
| McNaughton, A | 1 |
| Blackmore, T | 1 |
| McNaughton, H | 1 |
| Jain, NK | 1 |
| Agnihotri, SP | 1 |
| Sharma, KK | 1 |
| Gupta, S | 1 |
| Gupta, P | 1 |
| Goh, TL | 1 |
| Towns, CR | 1 |
| Jones, KL | 1 |
| Freeman, JT | 1 |
| Wong, CS | 1 |
1 review available for aminosalicylic acid and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Para-aminosalicylic acid: the return of an old friend.
Topics: Aminosalicylic Acid; Antitubercular Agents; Chemistry, Pharmaceutical; Drug Discovery; Extensively D | 2015 |
1 trial available for aminosalicylic acid and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Adult; Alkynes; Aminosalicylic Acid; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cr | 2014 |
11 other studies available for aminosalicylic acid and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
New amino acid esters of salicylanilides active against MDR-TB and other microbes.
Topics: Amino Acids; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Dose-Response Relationship, Drug; D | 2010 |
A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre.
Topics: Aminosalicylic Acid; Antitubercular Agents; Clinical Medicine; COVID-19; Extensively Drug-Resistant | 2022 |
Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Cycloserine; Deprescriptions; Diaryl | 2020 |
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
Topics: Aminosalicylic Acid; Antitubercular Agents; Carbapenems; Clofazimine; Communicable Disease Control; | 2017 |
Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment.
Topics: Aminosalicylic Acid; Antitubercular Agents; Ethambutol; Extensively Drug-Resistant Tuberculosis; Flu | 2018 |
Antibiotic Susceptibility Patterns of Mycobacterium tuberculosis Isolates from Guizhou Province of China Against 13 Antituberculosis Drugs.
Topics: Aminoglycosides; Aminosalicylic Acid; Antitubercular Agents; Capreomycin; China; Drug Resistance, Mu | 2015 |
French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS(®) in MDR-TB patients.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Female; | 2014 |
Early culture conversion and cure for extensively drug-resistant tuberculosis is possible with appropriate treatment: lessons learnt from a case study in South Africa.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Extensive | 2015 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Cl | 2016 |
Extensively drug resistance (XDR) tb is not always fatal.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Aza Compounds; Capreomycin; Clarithromycin; Clofa | 2009 |
Extensively drug-resistant tuberculosis: New Zealand's first case and the challenges of management in a low-prevalence country.
Topics: Acetamides; Adult; Aminosalicylic Acid; Antitubercular Agents; Aza Compounds; Cycloserine; Emigrants | 2011 |